AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00205283
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01061736
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT04917497
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
Trial: NCT03279302
Drug: Glepaglutide
RxNorm normalized name: Glepaglutide
DrugBank: Glepaglutide (DB14794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT05904184
Drug: Epoxy resin-based sealers (ERS)
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
Trial: NCT03819660
Drug: Amifampridine Phosphate 10 MG Oral Tablet
RxNorm normalized name: amifampridine phosphate 10 mg ORAL TABLET
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablets
Trial: NCT02341417
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
Trial: NCT00466518
Drug: Administration of sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg daily for 3 months
Trial: NCT03225716
Drug: Ulocuplumab
RxNorm normalized name: Ulocuplumab
DrugBank: Ulocuplumab (DB12018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulocuplumab is a type of protein called an antibody that attacks CXCR4
Trial: NCT03225716
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
Trial: NCT02808741
Drug: F901318 IR Fasting
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics area under curve
Trial: NCT01310816
Drug: IPI-926
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT01827930
Drug: Imatinib Mesylate 600 MG Oral Tablet
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib Mesylate for CP CML
Trial: NCT01827930
Drug: Imatinib Mesylate 400 MG Oral Tablet
RxNorm normalized name: Imatinib Mesylate 400 mg ORAL TABLET
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib Mesylate for CP CML
Trial: NCT01827930
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib Mesylate for CP CML
Trial: NCT00238303
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02623595
Drug: rhGM-CSF
RxNorm normalized name: rhGm-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune modulating agents
Trial: NCT02709928
Drug: TD-0714
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03783728
Drug: Rifapentine 600 mg orally
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Trial: NCT03783728
Drug: Isoniazid 900 mg orally
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Trial: NCT00491049
Drug: 0.5% levofloxacin eye drops
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02856802
Drug: Sumatriptan 10 mg Nasal Spray
RxNorm normalized name: Sumatriptan 10 MG Nasal Spray
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 μL nasal spray once
Trial: NCT00572234
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 week course of bupropion SR 150 mg, BID
Trial: NCT03737292
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
Trial: NCT03737292
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
Trial: NCT02358369
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost sustained release Ocular Insert
Trial: NCT02358369
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BID drops OU, 0.5% ophthalmic solution
Trial: NCT02760017
Drug: B. forficata
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03655717
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
Trial: NCT03655717
Drug: Placebo dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
Trial: NCT00999219
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00634959
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
Trial: NCT00634959
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet once daily while fasted on Days 1-10
Trial: NCT00634959
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg oral tablet once daily while fasted on Days 1-10
Trial: NCT00634959
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
Trial: NCT01320111
Drug: Paclitaxel and Sorafenib
RxNorm normalized name: paclitaxel and encequidar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day
Trial: NCT01320111
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
Trial: NCT02472691
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
Trial: NCT02472691
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
Trial: NCT01286948
Drug: Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)
RxNorm normalized name: levonorgestrel and ethinylestradiol
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated.
Trial: NCT04473144
Drug: Ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
Trial: NCT01070524
Drug: CHF 5188 pMDI
RxNorm normalized name: CHF-6333
DrugBank: CHF-6333 (DB17815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5188: fixed combination budesonide/carmoterol
Trial: NCT01070524
Drug: Budesonide extrafine pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide extrafine pMDI
Trial: NCT01070524
Drug: Seretide(r) Evohaler(r)
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
Trial: NCT00027456
Drug: Leptin A-100
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01884857
Drug: Metoprolol Succinate ER Tablets 50 mg
RxNorm normalized name: metoprolol succinate Extended Release Oral Tablet
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1\* 50 mg tablet once a day
Trial: NCT00972127
Drug: Neramexane
RxNorm normalized name: Neramexane
DrugBank: Neramexane (DB04926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg or 2x25mg tablets
Trial: NCT02625623
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
Trial: NCT02625623
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
Trial: NCT02625623
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
Trial: NCT00003817
Drug: dolasetron mesylate
RxNorm normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003817
Drug: granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003817
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003817
Drug: tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00661349
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
Trial: NCT00661349
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
Trial: NCT01810302
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Trial: NCT03001843
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia of only Ketamine
Trial: NCT00490659
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00490659
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01681576
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 320mg tablet once daily
Trial: NCT02435732
Drug: CINRYZE
RxNorm normalized name: Cinryze
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200U/kg IV dose with or without heparin, or 500U/kg IV dose
Trial: NCT03584087
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Terlipressin after EVL
Trial: NCT03368131
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
Trial: NCT03368131
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2 Ivgtt d1 q3w
Trial: NCT01522040
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous magnesium drip, titrated to effect until patient's symptoms improve
Trial: NCT00546039
Drug: Genistein
RxNorm normalized name: Genistein
DrugBank: Genistein (DB01645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 30 mg, oral daily for 3 to 6 weeks
Trial: NCT00004095
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004095
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01240655
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00587860
Drug: St. John's wort
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
Trial: NCT00115700
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
Trial: NCT00115700
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV Infusion day 1
Trial: NCT01257919
Drug: Azelaic Acid Foam
RxNorm normalized name: azelaic acid Topical Foam
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermal application of Azelaic Acid Foam
Trial: NCT01257919
Drug: Azelaic Acid Gel
RxNorm normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL [Azelaic Acid Gel]
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermal application of Azelaic Acid Gel
Trial: NCT01766817
Drug: BMS-986020
RxNorm normalized name: BMS-986020
DrugBank: BMS-986020 (DB14948)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766817
Drug: Placebo matching with BMS-986020
RxNorm normalized name: BMS-986020
DrugBank: BMS-986020 (DB14948)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227108
Drug: Moxetumomab Pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
Trial: NCT00995670
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
Trial: NCT00995670
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
Trial: NCT00995670
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
Trial: NCT02743429
Drug: dinutuximab beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days.
Trial: NCT00219232
Drug: Rivastigmine Transdermal Patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00261443
Drug: Lithium or Valproate with placebo (PBO)
RxNorm normalized name: valproate
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily
Trial: NCT00261443
Drug: Lithium or Valproate with Aripiprazole
RxNorm normalized name: valproate
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day
Trial: NCT02298192
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
Trial: NCT02878733
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
Trial: NCT01393756
Drug: Lenalidomide and R-CHOP
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
Trial: NCT00098605
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT01464242
Drug: Meglumine antimonate
RxNorm normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime® 20mg/kg/day IM daily for 20 days
Trial: NCT01464242
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400mg orally 3 times a day for 20 days
Trial: NCT03230474
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
Trial: NCT03230474
Drug: Morphine-Naloxone
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
Trial: NCT03011450
Drug: K-877
RxNorm normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
FDA approved: no
EMA approved: no
PMDA approved: no